190 related articles for article (PubMed ID: 18506148)
1. Oxaliplatin-DNA adduct formation in white blood cells of cancer patients.
Pieck AC; Drescher A; Wiesmann KG; Messerschmidt J; Weber G; Strumberg D; Hilger RA; Scheulen ME; Jaehde U
Br J Cancer; 2008 Jun; 98(12):1959-65. PubMed ID: 18506148
[TBL] [Abstract][Full Text] [Related]
2. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
4. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
[TBL] [Abstract][Full Text] [Related]
5. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
Schellens JH; Ma J; Planting AS; van der Burg ME; van Meerten E; de Boer-Dennert M; Schmitz PI; Stoter G; Verweij J
Br J Cancer; 1996 Jun; 73(12):1569-75. PubMed ID: 8664132
[TBL] [Abstract][Full Text] [Related]
6. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
7. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
[TBL] [Abstract][Full Text] [Related]
8. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells.
Rietbroek RC; van de Vaart PJ; Haveman J; Blommaert FA; Geerdink A; Bakker PJ; Veenhof CH
J Cancer Res Clin Oncol; 1997; 123(1):6-12. PubMed ID: 8996534
[TBL] [Abstract][Full Text] [Related]
9. Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.
Ma J; Verweij J; Planting AS; de Boer-Dennert M; van Ingen HE; van der Burg ME; Stoter G; Schellens JH
Br J Cancer; 1995 Mar; 71(3):512-7. PubMed ID: 7880732
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin-DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy.
Zimmermann M; Li T; Semrad TJ; Wu CY; Yu A; Cimino G; Malfatti M; Haack K; Turteltaub KW; Pan CX; Cho M; Kim EJ; Henderson PT
Mol Cancer Ther; 2020 Apr; 19(4):1070-1079. PubMed ID: 32029633
[TBL] [Abstract][Full Text] [Related]
11. Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations.
Hah SS; Sumbad RA; de Vere White RW; Turteltaub KW; Henderson PT
Chem Res Toxicol; 2007 Dec; 20(12):1745-51. PubMed ID: 18001055
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function.
Massari C; Brienza S; Rotarski M; Gastiaburu J; Misset JL; Cupissol D; Alafaci E; Dutertre-Catella H; Bastian G
Cancer Chemother Pharmacol; 2000; 45(2):157-64. PubMed ID: 10663631
[TBL] [Abstract][Full Text] [Related]
13. Speciation of oxaliplatin adducts with DNA nucleotides.
Zayed A; Jones GD; Reid HJ; Shoeib T; Taylor SE; Thomas AL; Wood JP; Sharp BL
Metallomics; 2011 Oct; 3(10):991-1000. PubMed ID: 21858382
[TBL] [Abstract][Full Text] [Related]
14. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
Veal GJ; Dias C; Price L; Parry A; Errington J; Hale J; Pearson AD; Boddy AV; Newell DR; Tilby MJ
Clin Cancer Res; 2001 Aug; 7(8):2205-12. PubMed ID: 11489793
[TBL] [Abstract][Full Text] [Related]
15. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.
Wang S; Zhang H; Scharadin TM; Zimmermann M; Hu B; Pan AW; Vinall R; Lin TY; Cimino G; Chain P; Vuyisich M; Gleasner C; Mcmurry K; Malfatti M; Turteltaub K; de Vere White R; Pan CX; Henderson PT
PLoS One; 2016; 11(1):e0146256. PubMed ID: 26799320
[TBL] [Abstract][Full Text] [Related]
16. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
17. Liquid chromatographic determination of oxaliplatin in blood using post-column derivatization in a microwave field followed by photometric detection.
Ehrsson H; Wallin I
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Oct; 795(2):291-4. PubMed ID: 14522033
[TBL] [Abstract][Full Text] [Related]
18. Towards biomarker-dependent individualized chemotherapy: exploring cell-specific differences in oxaliplatin-DNA adduct distribution using accelerator mass spectrometry.
Hah SS; Henderson PT; Turteltaub KW
Bioorg Med Chem Lett; 2010 Apr; 20(8):2448-51. PubMed ID: 20335033
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
Baur M; Drescher A; Gneist M; Dittrich C; Jaehde U
Cancer Chemother Pharmacol; 2008 Jan; 61(1):97-104. PubMed ID: 17396265
[TBL] [Abstract][Full Text] [Related]
20. Specificity of platinum-DNA adduct repair.
Chaney SG; Vaisman A
J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]